Clinical trial
A Dose Escalation Study of Tenofovir Alafenamide in Treatment-Naive Patients
NCT00036634 · Gilead Sciences, Industry · Completed
Key facts
| NCT number | NCT00036634 |
|---|---|
| Title | A Dose Escalation Study of Tenofovir Alafenamide in Treatment-Naive Patients |
| Official title | A Phase 1/2, Randomized, Double-Blind, Active Controlled, Dose Escalation Study of the Safety, Tolerance, Pharmacokinetic,, and Antiviral Activity of GS-7340-02 in Antiretroviral-Naive Patients Who Are Chronically Infected With HIV-1 |
| Lead sponsor | Gilead Sciences, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Tenofovir DF, Tenofovir alafenamide |
| Enrollment | 30 |
| Start date | Mar 1, 2002 |
| Primary completion | Feb 1, 2003 |
| Completion | Feb 1, 2003 |
| First posted | May 14, 2002 |
| Last update posted | Jan 15, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: